Pharmaceutical - USA, AbbVie

Filter

Current filters:

USAAbbVie

Popular Filters

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

14-07-2014

Ireland-headquartered Shire, which just on Friday confirmed it had finally entered talks with suitor…

AbbVieAdalimumabFinancialIrelandMergers & AcquisitionsPharmaceuticalShireUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

AbbVie justifies its position regarding Shire offer

AbbVie justifies its position regarding Shire offer

26-06-2014

US drugmaker AbbVie has set out its ‘strategic rationale’ for its proposal to buy Ireland headquartered…

AbbVieFinancialPharmaceuticalShire PharmaceuticalsUSA

AbbVie raises expectations driven by strong performance

AbbVie raises expectations driven by strong performance

24-06-2014

US drugmaker AbbVie has raised the midpoint of its full-year 2014 earnings-per-share guidance by six…

AbbVieAmortizationBusiness FinanceFinanceFinancialGuidancePharmaceuticalUSAUSD

EMA validates Marketing Authorization Applications for AbbVie’s hepatitis C treatment

EMA validates Marketing Authorization Applications for AbbVie’s hepatitis C treatment

17-06-2014

US drugmaker AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational,…

AbbVieAnti-viralsPharmaceuticalRegulationRitonavir TabletsUSA

Biogen and AbbVie release Phase III data for MS treatment

Biogen and AbbVie release Phase III data for MS treatment

17-06-2014

US biotech firm Biogen Idec and US drugmaker AbbVie have announced positive top-line results from the…

AbbVieBiogen IdecCNS DiseasesdaclizumabPharmaceuticalResearchUSA

AbbVie gains FDA orphan designation for Humira in uveitis

21-05-2014

The US Food and Drug Administration granted US drugmaker AbbVie’s blockbuster rheumatoid arthritis…

AbbVieHumiraOphthalmicsPharmaceuticalRegulationUSA

Breakthrough designation for B-MS/AbbVie’s MM drug elotuzumab

19-05-2014

The US Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody…

AbbVieBristol-Myers SquibbelotuzumabOncologyPharmaceuticalRegulationUSA

AbbVie files for EU marketing approval for its all-oral, interferon-free hepatitis C therapy

AbbVie files for EU marketing approval for its all-oral, interferon-free hepatitis C therapy

08-05-2014

US drugmaker AbbVie has submitted marketing authorization applications to the European Medicines Agency…

AbbVieAnti-viralsPharmaceuticalRegulationUSA

AbbVie files NDA for oral, interferon-free treatment of hepatitis C

22-04-2014

US drugmaker AbbVie has submitted its New Drug Application to the US Food and Drug Administration for…

AbbVieAnti-viralsEnanta PharmaceuticalsFinancialNorth AmericaPharmaceuticalRegulationUSA

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

14-04-2014

US drugmaker AbbVie has revealed promising new results from its hepatitis C development program at the…

AbbVieAnti-viralsPharmaceuticalResearchUSA

AbbVie presents positive Phase III results in patients with chronic hepatitis C

AbbVie presents positive Phase III results in patients with chronic hepatitis C

04-03-2014

The first detailed results from US drugmaker AbbVie’s pivotal Phase III study, PEARL-III, have been…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

AbbVie’s hepatitis C Phase III trials all record top results

AbbVie’s hepatitis C Phase III trials all record top results

04-02-2014

US drugmaker AbbVie has announced the completion of its Phase III clinical program and released results…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

AbbVie reports 96% response in Phase III hepatitis C study

AbbVie reports 96% response in Phase III hepatitis C study

10-12-2013

US drugmaker AbbVie (NYSE: ABBV)has released Phase III results for the investigational three direct-acting-antiviral…

AbbVieAnti-viralsAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

AbbVie releases positive Phase III results for oral hepatitis C program

AbbVie releases positive Phase III results for oral hepatitis C program

18-11-2013

US drugmaker AbbVie has released the first Phase III results for the investigational three direct-acting-antiviral…

AbbVieAntibiotics and Infectious diseasesNorth AmericaPharmaceuticalResearchUSA

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins

13-11-2013

New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Back to top